Zhenzhun Biotechnology (Shanghai) Co. Ltd. (hereinafter referred to as "ZZ Bio"), a digital PCR company, has recently completed a Series A financing round of over CNY 100 million, exclusively invested by Huiyuan Capital, a professional investment institution in the healthcare industry. Huiyuan Capital will enable the company to accelerate the penetration and promotion of digital PCR in life sciences and clinical areas by importing rich industrial resources.

This round of financing will be used for clinical registration, marketing and scale up of microchip-based digital PCR products as well as the development of several kits.

Zhenzhun Biotechnology (Shanghai) Co. Ltd. 

CACLP Booth NO.B3-2211

Compared with traditional real-time fluorescence PCR, digital PCR can achieve absolute quantification of nucleic acid copy number and detection sensitivity of up to 0.01%, which has a wide application prospect. After more than ten years of development, among various technical paths, "micro-chip" has gradually become the mainstream technical route of digital PCR with its excellent homogeneity, stability and high efficiency, and is also the technical direction chosen by many international giants.

ZZ Bio was founded in 2016 and headquartered in Shanghai, with R&D and production centres in various locations across China, which is the leader in micro-chip digital PCR technology in China. The company's team comes from well-known multinational companies and research institutions, and has rich experience in R&D and industrialisation of core technologies such as micro and nano processing, precision instruments, biological reagents, clinical applications and software algorithms, and has broken through the technical difficulties of micro-chip manufacturing and surface treatment processes, and successfully achieved low-cost mass production.